VEGFA and hereditary clear cell renal cell carcinoma: Since most renal cell carcinoma patients are accompanied by VHL gene mutations, which lead to activation of the HIF pathway and hypoxia, anti-angiogenic drugs are mainly used to directly or indirectly block the downstream signaling pathways of VEGF and its receptors in the treatment of renal cell carcinoma to achieve intervention.